Table 32.1 Open in new tab Prevalence...

Table 32.1

Prevalence and incidence of heart failure and diabetes mellitus in related circumstances

	Prevalence			Incidence
	General population	HF in DM	DM in HF	HF in DM	DM in HF
Population-based studies^a	DM 4–15% (population and age dependent) HF 1–4% (age dependent)⁸^,⁹^,¹¹	12% 22% aged 〉64 years¹⁰	6–44%¹⁸^,¹⁹	Hazard ratio 1.74–8 (age dependent) Odds ratio 2.0–2.8^1,⁸^,¹⁰	28.8% with DM vs. 18.3% without DM (3 years)²⁶
Clinical trials	N/A	N/A	11–41%¹²^,^–¹⁶	2.3—11.9 per 1000 person-years (HbA_1c related)²⁰ 13.3% in placebo group of MICRO-HOPE (4.2 years)²³	5.9–7.4% (3 years) 13–20% (7.7 years, NYHA class dependent)²⁷^,^–²⁹

	Prevalence			Incidence
Population-based studies^a	DM 4–15% (population and age dependent) HF 1–4% (age dependent)⁸^,⁹^,¹¹	12% 22% aged 〉64 years¹⁰	6–44%¹⁸^,¹⁹	Hazard ratio 1.74–8 (age dependent) Odds ratio 2.0–2.8^1,⁸^,¹⁰	28.8% with DM vs. 18.3% without DM (3 years)²⁶
Clinical trials	N/A	N/A	11–41%¹²^,^–¹⁶	2.3—11.9 per 1000 person-years (HbA_1c related)²⁰ 13.3% in placebo group of MICRO-HOPE (4.2 years)²³	5.9–7.4% (3 years) 13–20% (7.7 years, NYHA class dependent)²⁷^,^–²⁹

Prevalence

Incidence

General population

HF in DM

DM in HF

HF in DM

DM in HF

Population-based studies^a

DM 4–15% (population and age dependent)

HF 1–4% (age dependent)⁸^,⁹^,¹¹

12%

22% aged 〉64 years¹⁰

6–44%¹⁸^,¹⁹

Hazard ratio 1.74–8 (age dependent)

Odds ratio 2.0–2.8^1,⁸^,¹⁰

28.8% with DM vs. 18.3% without DM (3 years)²⁶

Clinical trials

N/A

11–41%¹²^,^–¹⁶

2.3—11.9 per 1000 person-years (HbA_1c related)²⁰

13.3% in placebo group of MICRO-HOPE (4.2 years)²³

5.9–7.4% (3 years)

13–20% (7.7 years, NYHA class dependent)²⁷^,^–²⁹

DM, diabetes mellitus; HF, heart failure.

Includes epidemiological, registry and population-based studies with endpoints including hospitalization.